"instanceType","uuid:ID","rationale","id","versionIdentifier"
"StudyVersion","14a5bc1a-a286-4576-ae86-60515c3157f4","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2"
